In addition to acting as current President and Chief Executive Officer (CEO) of Zenith Epigenetics, Donald McCaffrey is the Co-Founder, President, & CEO of Resverlogix Corp. (TSX-RVX). He has over 35 years of business experience including 15 years of drug discovery & development. Donald led Resverlogix through significant changes and achievements from its initial days as a private company to becoming a TSX listed company. He has personally raised over $300 million for research and clinical development in the areas of cardiovascular disease, diabetes mellitus, Alzheimer’s disease and other serious indications.
Donald’s expertise in corporate operations has attracted an international team of experts in research, development, and corporate affairs to Resverlogix. Under Donald’s guidance, Resverlogix was honored with multiple awards, the most prestigious being the 2008 World Economic Forum (WEF) Technology Pioneer award in Davos, Switzerland.
As President and CEO of Resverlogix, Mr. McCaffrey spearheaded the development and spin-out of Resverlogix’s subsidiary RVX Therapeutics Inc. to Zenith Epigenetics Corp., a newly-incorporated company. As President and CEO of Zenith Epigenetics, Mr. McCaffrey assembled a world class Oncology team to further the development of this program. In addition to Zenith Epigenetics Corp., Mr. McCaffrey also serves on the Board of Directors of Resverlogix Corp.
Donald’s career accomplishments have been recognized by the business community and peers, as he was nominated for Ernst & Young Entrepreneur of the Year three times. He has also arranged support for several non-profit organizations, including: the Libin Cardiovascular Institute of Alberta, Juvenile Diabetes Research Foundation, Sanofi Biogenius Canada (MindFuel), United Way, Mount Royal University Foundation, Alberta Children's Hospital, Edge School Foundation, Education Matters, Calgary Urban Project Society Literacy Program, Movember Foundation, and Enbridge Ride to Conquer Cancer.